ES2197213T3 - Uso de pramipexol como agente neuroprotector. - Google Patents
Uso de pramipexol como agente neuroprotector.Info
- Publication number
- ES2197213T3 ES2197213T3 ES95942961T ES95942961T ES2197213T3 ES 2197213 T3 ES2197213 T3 ES 2197213T3 ES 95942961 T ES95942961 T ES 95942961T ES 95942961 T ES95942961 T ES 95942961T ES 2197213 T3 ES2197213 T3 ES 2197213T3
- Authority
- ES
- Spain
- Prior art keywords
- accordance
- pramipexole
- enantiomer
- dose
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title abstract description 30
- 230000001067 neuroprotector Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 9
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- 230000000626 neurodegenerative effect Effects 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000002008 hemorrhagic effect Effects 0.000 claims description 3
- 230000001146 hypoxic effect Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000003961 neuronal insult Effects 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000037920 primary disease Diseases 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 11
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 11
- 229960004502 levodopa Drugs 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004090 neuroprotective agent Substances 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DGNHGRLDBKAPEH-NJFSPNSNSA-N 3-amino-2-methyl-2-(114C)methylpropanoic acid Chemical compound [14CH3]C(C(=O)O)(CN)C DGNHGRLDBKAPEH-NJFSPNSNSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000037169 Retrograde Degeneration Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- -1 cytosine monophosphate Chemical class 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011556 gerbil model Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- HOKBIQDJCNTWST-UHFFFAOYSA-N phosphanylidenezinc;zinc Chemical compound [Zn].[Zn]=P.[Zn]=P HOKBIQDJCNTWST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000013417 toxicology model Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Semiconductor Memories (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US357121 | 1994-12-15 | ||
| US08/357,121 US5650420A (en) | 1994-12-15 | 1994-12-15 | Pramipexole as a neuroprotective agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2197213T3 true ES2197213T3 (es) | 2004-01-01 |
Family
ID=23404382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95942961T Expired - Lifetime ES2197213T3 (es) | 1994-12-15 | 1995-12-12 | Uso de pramipexol como agente neuroprotector. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5650420A (fr) |
| EP (1) | EP0797439B1 (fr) |
| JP (2) | JP4796219B2 (fr) |
| KR (2) | KR100420252B1 (fr) |
| CN (1) | CN1177586C (fr) |
| AT (1) | ATE238790T1 (fr) |
| AU (1) | AU712666B2 (fr) |
| CA (1) | CA2207323C (fr) |
| DE (1) | DE69530606T2 (fr) |
| DK (1) | DK0797439T3 (fr) |
| ES (1) | ES2197213T3 (fr) |
| MX (1) | MX9704377A (fr) |
| NZ (1) | NZ298606A (fr) |
| PT (1) | PT797439E (fr) |
| SI (1) | SI0797439T1 (fr) |
| WO (1) | WO1996018395A1 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156777A (en) * | 1994-12-15 | 2000-12-05 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
| DE19701619B4 (de) * | 1997-01-17 | 2007-10-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Pramipexol zur Behandlung des restless legs syndroms |
| US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE69928521T2 (de) * | 1998-05-15 | 2006-07-27 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit |
| EP1591119A3 (fr) * | 1998-05-15 | 2007-03-28 | Pharmacia & Upjohn Company LLC | Pramipexole pour le traitement des maladies du système nerveux central, en particulier la maladie de Parkinson |
| US6750235B1 (en) | 1999-09-30 | 2004-06-15 | The General Hospital Corporation | Pramipexole as a treatment for cocaine craving |
| PE20011074A1 (es) | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
| WO2002017931A1 (fr) * | 2000-09-01 | 2002-03-07 | Xiaomin Wang | Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20020165246A1 (en) * | 2001-03-05 | 2002-11-07 | Andrew Holman | Administration of sleep restorative agents |
| FR2825087B1 (fr) * | 2001-05-22 | 2005-01-14 | Galderma Res & Dev | Analogues de la vitamine d |
| DE10137453A1 (de) * | 2001-08-02 | 2003-02-20 | Boehringer Ingelheim Pharma | Pramlpexol als Antikonvulsivum |
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| AU2002360600B2 (en) * | 2001-12-11 | 2007-11-29 | University Of Virginia Patent Foundation | Use of pramipexole to treat amyotrophic lateral sclerosis |
| US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
| US20030166696A1 (en) * | 2002-01-24 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pramipexole for the treatment of HIV dementia |
| DE10203103A1 (de) * | 2002-01-25 | 2003-08-07 | Boehringer Ingelheim Pharma | Pramipexol zur Behandlung von HIV Demenz |
| PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| GB0221513D0 (en) * | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
| DE10333393A1 (de) * | 2003-07-23 | 2005-02-24 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol |
| JP2007518754A (ja) * | 2004-01-22 | 2007-07-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物 |
| WO2006012277A2 (fr) * | 2004-06-30 | 2006-02-02 | Amr Technology, Inc. | Procede biocatalytique de fabrication de pramipexole enrichi enantiomeriquement |
| EP2431026A1 (fr) | 2004-08-13 | 2012-03-21 | Boehringer Ingelheim International GmbH | Formulation de pastille à libération prolongée contenant du pramipexole ou l'un de ses sels pharmaceutiquement acceptable, son procédé de fabrication et utilisation associée |
| CA2619217A1 (fr) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestauration avec du pramipexole r(+) |
| US20080262053A1 (en) * | 2005-10-18 | 2008-10-23 | Juergen Reess | Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls) |
| ITMI20060044A1 (it) * | 2006-01-13 | 2007-07-14 | Dipharma Spa | Sintesi di intermedi pr la preparazione di pramipexolo |
| US20070259930A1 (en) * | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
| US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| ES2379117T3 (es) * | 2006-05-16 | 2012-04-20 | Knopp Neurosciences, Inc. | Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas |
| CL2007003130A1 (es) * | 2006-10-30 | 2008-05-30 | Boehringer Ingelheim Int | Uso de una formulacion de liberacion inmediata con un ingrediente activo seleccionado de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol monohidrato o una sal farmaceuticamente aceptable de este, para el tratamiento de la enferme |
| CN104107177A (zh) * | 2006-12-14 | 2014-10-22 | 诺普生物科学有限责任公司 | (r)-普拉克索的组合物以及使用该组合物的方法 |
| US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| EP2137171A4 (fr) | 2007-03-14 | 2010-05-19 | Knopp Neurosciences Inc | Synthèse de benzothiazole diamines substituées et purifiées du point de vue chiral |
| CA2734491A1 (fr) * | 2008-08-19 | 2010-02-25 | Knopp Neurosciences, Inc. | Compositions et procedes employant du (r)-pramipexole |
| BRPI1010084A2 (pt) * | 2009-06-19 | 2015-08-25 | Knopp Neurosciences Inc | Método para tratar esclerose lateral amiotrófica em um paciente |
| US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| SMT202100119T1 (it) | 2013-07-12 | 2021-05-07 | Knopp Biosciences Llc | Trattamento dei livelli elevati di eosinofili e/o basofili |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| WO2015023786A1 (fr) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b |
| US9763918B2 (en) | 2013-08-13 | 2017-09-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
| WO2016194015A2 (fr) | 2015-06-04 | 2016-12-08 | Chiarugi Alberto | Utilisation de r(+)-pramipexole (dexpramipexole) pour le traitement d'une ischémie focale cérébrale |
| KR20250108755A (ko) | 2017-03-27 | 2025-07-15 | 체이스 테라퓨틱스 코포레이션 | 시누클레인병변을 치료하기 위한 조성물 및 방법 |
| CN111918649B (zh) | 2018-03-16 | 2024-07-30 | 脑科学香料株式会社 | 缺氧障碍、缺血再灌注障碍或炎症的预防或治疗剂，移植用细胞保护剂，及生物体防腐剂 |
| WO2020139520A1 (fr) * | 2018-12-27 | 2020-07-02 | Chase Therapeutics Corporation | Combinaisons anti-neurodégénératives à base de dompéridone et leur utilisation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0186087B1 (fr) * | 1984-12-22 | 1989-08-23 | Dr. Karl Thomae GmbH | Tétrahydro-benzothiazoles, leur procédé de préparation et leur utilisation comme intermédiaires ou médicaments |
| DE3447075A1 (de) * | 1984-12-22 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
| DE3843227A1 (de) * | 1988-12-22 | 1990-07-05 | Boehringer Ingelheim Kg | Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
-
1994
- 1994-12-15 US US08/357,121 patent/US5650420A/en not_active Expired - Lifetime
-
1995
- 1995-12-12 PT PT95942961T patent/PT797439E/pt unknown
- 1995-12-12 EP EP95942961A patent/EP0797439B1/fr not_active Expired - Lifetime
- 1995-12-12 DK DK95942961T patent/DK0797439T3/da active
- 1995-12-12 SI SI9530667T patent/SI0797439T1/xx unknown
- 1995-12-12 KR KR1019970704012A patent/KR100420252B1/ko not_active Expired - Fee Related
- 1995-12-12 AU AU44134/96A patent/AU712666B2/en not_active Ceased
- 1995-12-12 NZ NZ298606A patent/NZ298606A/en not_active IP Right Cessation
- 1995-12-12 CA CA002207323A patent/CA2207323C/fr not_active Expired - Fee Related
- 1995-12-12 JP JP51908196A patent/JP4796219B2/ja not_active Expired - Fee Related
- 1995-12-12 AT AT95942961T patent/ATE238790T1/de active
- 1995-12-12 DE DE69530606T patent/DE69530606T2/de not_active Expired - Lifetime
- 1995-12-12 KR KR10-2003-7013938A patent/KR100451874B1/ko not_active Expired - Lifetime
- 1995-12-12 WO PCT/US1995/015613 patent/WO1996018395A1/fr not_active Ceased
- 1995-12-12 ES ES95942961T patent/ES2197213T3/es not_active Expired - Lifetime
- 1995-12-12 CN CNB95196769XA patent/CN1177586C/zh not_active Expired - Fee Related
-
1997
- 1997-06-13 MX MX9704377A patent/MX9704377A/es unknown
-
2007
- 2007-05-30 JP JP2007143213A patent/JP2007217432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996018395A1 (fr) | 1996-06-20 |
| CN1177586C (zh) | 2004-12-01 |
| CA2207323C (fr) | 2006-10-10 |
| JPH10510809A (ja) | 1998-10-20 |
| JP2007217432A (ja) | 2007-08-30 |
| DE69530606T2 (de) | 2004-02-19 |
| SI0797439T1 (en) | 2003-12-31 |
| KR20040000443A (ko) | 2004-01-03 |
| AU712666B2 (en) | 1999-11-11 |
| KR100420252B1 (ko) | 2004-04-21 |
| CA2207323A1 (fr) | 1996-06-20 |
| CN1169677A (zh) | 1998-01-07 |
| EP0797439A1 (fr) | 1997-10-01 |
| AU4413496A (en) | 1996-07-03 |
| KR100451874B1 (ko) | 2004-10-08 |
| ATE238790T1 (de) | 2003-05-15 |
| MX9704377A (es) | 1998-07-31 |
| EP0797439B1 (fr) | 2003-05-02 |
| JP4796219B2 (ja) | 2011-10-19 |
| DE69530606D1 (de) | 2003-06-05 |
| PT797439E (pt) | 2003-08-29 |
| US5650420A (en) | 1997-07-22 |
| DK0797439T3 (da) | 2003-08-25 |
| NZ298606A (en) | 2001-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2197213T3 (es) | Uso de pramipexol como agente neuroprotector. | |
| US6156777A (en) | Use of pramipexole as a neuroprotective agent | |
| CA2468747C (fr) | Utilisation de pramipexole pour traiter la sclerose laterale amyotrophique | |
| AU762128B2 (en) | Agents with an antidepressive effect | |
| US5589513A (en) | Pharmaceutical composition and process for the preparation thereof | |
| CA2327299A1 (fr) | Cabergoline et pramipexole: nouvelles utilisations et combinaisons | |
| US6495586B2 (en) | Scytonemin and methods of using thereof | |
| KR100196445B1 (ko) | 신경보호활성을 갖는 알파-디하이드로에르고크립틴 약제학적 제제 | |
| BRPI0714985A2 (pt) | inibidores de monoamina oxidase éteis para tratar distérbios da retina externa | |
| HK1150153B (en) | Use of pramipexole to treat amyotrophic lateral sclerosis | |
| AU2008200886A1 (en) | Use of Pramipexole to Treat Amyotrophic Lateral Sclerosis | |
| ZA200404433B (en) | Use of pramipexole to treat amyotrophic lateral sclerosis. | |
| HK1156239A (en) | Use of pramipexole to treat amyotrophic lateral sclerosis | |
| HK1156238A (en) | Use of pramipexole to treat amyotrophic lateral sclerosis | |
| EP1599195A1 (fr) | Utilisation de derives d'acide pipecolique non immunosuppresseurs pour induire une differenciation chondrogenique |